Morgan Stanley
RNAZ icon

Morgan Stanley’s TransCode Therapeutics RNAZ Stock Holding History

Morgan Stanley’s Portfolio RNAZ Stock Details RNAZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-179
Closed -$2.48K – 8247
2025
Q1 		$2.48K Buy
179
+168
+1,527% +$21.5K ﹤0.01% 7134
2024
Q4 		$1.02K Hold
11
– – ﹤0.01% 7271
2024
Q3 		$5.71K Hold
11
– – ﹤0.01% 6874
2024
Q2 		$10.1K Buy
+11
New +$9.79K ﹤0.01% 6679
2023
Q1 		– Hold
0
– -$784 – 7813
2022
Q4 		– Hold
0
– – – 7505

Other funds holding RNAZ

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SC
SouthState Corp Winter Haven, Florida $2.14B AUM 18.39% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Morgan Stanley's RNAZ Position: Q2 2025 in Review

Morgan Stanley sold out of TransCode Therapeutics (RNAZ) in Q2 2025, closing a stake of 179 shares — an estimated $2.48K sold.

Morgan Stanley first reported a position in RNAZ in Q2 2024 and held it in 4 quarters. The position peaked at $10.1K in Q2 2024. 9 funds tracked by Wall St. Rank hold RNAZ as of Q2 2025.

  • Morgan Stanley reported no remaining TransCode Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Morgan Stanley sold 179 TransCode Therapeutics shares in Q2 2025, an estimated $2.48K.
  • Morgan Stanley first reported a position in TransCode Therapeutics in Q2 2024 and held it in 4 quarters.
  • Morgan Stanley's TransCode Therapeutics position peaked at $10.1K in Q2 2024.
  • 9 funds tracked by Wall St. Rank held TransCode Therapeutics as of Q2 2025.

Based on Morgan Stanley's 13F filing for Q2 2025, filed 15 Aug 2025.